| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Laboratory of Inorganic Chemistry, ETH Hönggerberg–HCI, Zürich, Switzerland
2 Scuola Internazionale Superiore di Studi Avanzati and INFM–DEMOCRITOS National Simulation Center, Trieste, Italy
Reprint requests to: Professor Paolo Carloni, International School for Advanced Studies, via Beirut 4,34014, Trieste, Italy; e-mail: carloni{at}sissa.it; fax: +39-040-3787-528
(RECEIVED April 8, 2002; FINAL REVISION June 28, 2002; ACCEPTED July 2, 2002)
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.0206702.
 |
Abstract |
|---|
 TOP Abstract IntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
Keywords: HIV-1 protease; molecular dynamics; protein flexibility; compensatory mutations; drug resistance
|
Introduction |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
). Apparently, these variants are able to evolve resistance by complementary strategies: several active-site (Fig. 1, red) and nonactive-site (Fig.1, green) mutations reduce the affinity for both drugs and substrates. This may be achieved by disrupting favorable drug-protease interactions (Chen et al. 1995; Markowitz et al. 1995; Schaffer and Verkhivker 1998; Tawa et al. 1998; Mahalingam et al. 1999, 2001; Rosin et al. 1999; Hong et al. 2000; Wang and Kollman 2001). In contrast, "compensatory mutations" (Fig. 1, blue) are able to enhance the protease activity that is decreased by the active-site mutations (Gulnik et al. 2000).
|
In the last years, several laboratories have pointed to the difference in conformational flexibility between wild type and mutants as a possible key factor for the catalytic activity (Chen et al. 1995; Gulnik et al. 2000). This proposal is corroborated by X-ray crystallography and theoretical data. In fact, in the structures solved so far that contain compensatory mutations (K45I [Mahalingam et al. 2001], M46I [Chen et al. 1995], L90M [Hong et al. 2000]), the mutated enzymes turn out to be less flexible as indicated by lower B factors. The motion of the flap tips in the free HIV-1 PR has also been investigated with nuclear magnetic resonance (NMR) (Ishima et al. 1999; Freedberg et al. 2002) and molecular dynamics simulation (Scott and Schiffer 2000). These studies indicate that the flaps are highly mobile and can adopt a large number of conformations on the ns to ms timescale, thus suggesting that mutations in the flaps can be very important for the kinetics of substrate and inhibitor binding. A classical molecular dynamics (MD) study on wild type and M46I variant free enzyme, arguably the most common and representative compensatory mutation (Ho et al. 1994) (Fig. 1
), has indicated that the two systems differ in their flexibility and, in particular, that this mutation appears to stabilize the closed conformation of the flaps (Collins et al. 1995). However, the M46I mutation appears to have little effect on the HIV-1 PR affinity for most of the inhibitors (Pazhanisamy et al. 1996; Schock et al. 1996), thus indicating that other factors, besides the binding affinity must play a role in this kind of mutation.
Our recent quantum chemical and MD calculations on the complex between L63P HIV-1 PR3 and a peptide substrate (SUB) have indicated that the overall flexibility of the enzyme/substrate complex is an essential ingredient for the enzymatic function (Piana et al. 2002). Specifically, large-scale motions of the enzyme have been found to be essential to drive the substrate in an appropriate position in which the catalytic cleavage can occur (Piana et al. 2002). Similar conclusions have been drawn for other enzymatic systems (Lau and Bruice 2000; Radkiewicz and Brooks 2000). This has led to the suggestion that conformational flexibility might play a role not only in substrate or inhibitor binding, but also for the increase in catalytic efficiency.
Here, we have used multi-ns MD on complexes of L63P enzyme (which can be considered as a representative of the wild type enzyme3) and the double mutant M46I-L63P to shed light on this issue. Specifically, we have prolonged our simulation of the L63P/SUB complex to 11 ns and performed simulations on the same time scale for the complex between L63P-M46I HIV-1 PR and SUB as well as with the corresponding gem-diol intermediate (INT) of the catalytic cycle (Hyland et al. 1991) (Chart 1).
|
|
Results and Discussion |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
1.0–1.4 Å) (Fig. 1SI of Supplemental Material). A comparison of the MD-averaged structures of the four complexes (Fig. 2S and 2SI of Supplemental Material) further confirms that the overall folding is well maintained in the four systems.
|
and Table 2SI of Supplemental Material). This result is in line with previous MD calculations (Harte et al. 1992; Luo et al. 1998) and with experimental data (Chen et al. 1995).
|
|
); the few hydrogen bonds that are lost are located between SUB (or INT) and the cleavage site region. Interestingly, two different binding modes are observed for the side chain of Gln P2' (Fig. 2B,D), a residue that is important for HIV-1 PR activity (Poorman et al. 1991; Polgár et al. 1994; Szeltner and Polgár 1996). In the L63P/INT simulation the binding is the same as in the crystal structure; in the other three simulations the O
of Gln P2' is hydrogen bonded to the backbone amide nitrogen of Asp 29'.
Finally, we note that the hydrogen bonds in the loops region are mostly preserved, although occasional local unfolding events are observed in the glycine-rich tip of the flap region (residues 49–52) (Table 1SI of Supplemental Material).
We conclude that the structural differences between L63P and the L63P-M46I MD-averaged structures are small. This agrees with a structural study on the M46I-L63P-V82T-I84V quadruple mutant (Chen et al. 1995), which is found to exhibit only a minor rearrangement of the flaps relative to wild type.
Dynamics: Local fluctuations
We now turn our attention to the flexibility of the protein, which is the main focus of this work. The conformational fluctuations of the adducts in the sub-ns time scale can be described in terms of generalized order parameters S2 for which direct contact with NMR data (Lipari and Szabo 1982a) can be made (Lipari and Szabo 1982b; Luo et al. 1998). The calculated values (Fig. 3) turn out to be very similar in the four systems and are in excellent agreement with the available experimental data (Nicholson et al. 1995; Tjandra et al. 1996; Freedberg et al. 1998). The only residue that systematically exhibits large deviations is Gly 68(68') whose calculated order parameter (0.6) is much lower than the experimental values (0.85–0.9). This discrepancy might arise from the fact that Gly68(68') is part of the 68(68')–71(71') mobile loop. Indeed, this loop encompasses the solvent-exposed His69(69') which is very likely to be affected by proton exchange at the imidazole ring on time scales longer than the one simulated here. This proton exchange, which cannot be accounted for in our MD simulations, could influence the dynamics of the adjacent Gly 68 residue giving rise to the discrepancy in the order parameters.
|
). In all four systems, the largest flexibility is observed in the regions characterized by the presence of one or more residues with a low order parameter (residues 16–18, 37–42, 68–71, and 78–82 in Fig. 3 and 4A) (Nicholson et al. 1995; Tjandra et al. 1996; Freedberg et al. 1998), which mostly correspond to the protein loops. This result is in agreement with a recent study (Zoete et al. 2002) where 73 crystal structures of HIV-1 PR are compared; based on the differences in the crystal structures in combination with MD results, the authors conclude that these are the regions of largest flexibility.
|
Differences in flexibility are also observed between L63P and the L63P-M46I mutant in complex with either SUB or INT (Fig. 4A). The flap elbows (residue 38–42) turn out to be more flexible in the double mutant. However, the rest of the flaps (residues 45–49 and 52–57), as well as SUB/INT (Fig. 4B,C), are more flexible in the L63P enzyme. Accordingly, although the average conformation of residue 46(46') is very much the same in the four simulations (Table 1 and 2SI), the standard deviations of the torsional angles clearly indicate that SUB is more flexible than INT and L63P is more flexible than M46I-L63P. All these findings are in line with previous MD calculations of the free M46I enzyme in vacuum (Collins et al. 1995), which indicated that the M46I mutation strongly influences the dynamics of flap opening.
Thus, we conclude that the M46I mutation induces mostly a lower flexibility, although the MD-averaged structural properties are similar.
Dynamics: Large-scale motions
The overall flexibility of the system can be further analyzed in terms of correlations between the substrate and the protein motions (Fig. 5a–d) (Harte et al. 1992; Radkiewicz and Brooks 2000; Piana et al. 2002). The corresponding dynamic cross-correlation matrix indicates that in all four systems the substrate motions are tightly coupled to fluctuations in the tip of the flaps (residue 48–51) and in the cleavage site (residues 25–30) (Fig. 5a–d). This is consistent with the H-bond pattern described in Table 2, which shows that the hydrogen bonds between SUB (or INT) and the loops are fully maintained. To a lesser extent, motions of the substrate appear to be correlated with the 78–85 loop, which is crucial for substrate selectivity (Stebbins et al. 1997) and drug resistance (Gulnik et al. 2000).
|
In this section, we attempt to relate the different dynamical properties of the ligand (either SUB or INT, Scheme 1) to the two steps of the enzymatic mechanism, namely the formation of INT and the subsequent cleavage of the C-N bond (Scheme 1). Previously, we have shown that the substrate/enzyme distance da (Scheme 3) is an appropriate reaction coordinate for the first step of the enzymatic reaction (Piana et al. 2002). In particular, the reactive wild type/SUB conformations have been shown to be characterized by short da values of da<dmin 7.5.
A plot of da as a function of time in both L63P and L63P-M46I/SUB complexes is presented in Fig. 6a. The L63P HIV-PR samples often-reactive conformations (as defined by a critical distance da<7.5Å) for short times. However, in the mutant MD simulation da samples once a critical state for a long time. Such an event is observed only once in the simulation and could be an artifact because of the limited statistics. However, analysis of the da distance distribution indicates that while the average da in L63P (7.91 Å) and in the double mutant (7.89 Å) are very similar, because of the difference in flexibility, the standard deviation of the double mutant (0.20 Å) is smaller than that of the L63P enzyme (0.24 Å). The same difference in flexibility is obtained if only the first or second half of the simulations is considered (Table 3SI). We conclude that within the limits of the short timescale investigated, which is several orders of magnitude smaller than that relevant for the biological catalysis, the simulations indicate that substrate flexibility and sampling of the reactive conformation in the two cases could be different. The high sensitivity of the reaction free energy barrier on da (Piana et al. 2002), strongly suggests that even small differences in the probability distribution of da could account for the differences in catalytic activity between L63P and the double mutant (Schock et al. 1996).
|
shows the analogous plot for the adducts with INT. As for the substrate complex, the fluctuations of da are larger in L63P, consistent with the larger flexibility of L63P (Fig. 4B,C). However, in this case INT is closer to the active site in the M46I-L63P mutant simulations (average da 7.5 Å) with respect to L63P (7.7 Å). The differences in structural and dynamical properties of INT at the active site might also be related to its reactivity. However, the direct implication of differences in INT flexibility and conformation on the catalytic activity has not yet firmly been established through a detailed quantum-mechanical study. Such a flexibility-assisted catalysis mechanism may also provide a rationale for the strikingly different behavior of protease/peptide adducts. Indeed, peptides with similar affinity have been found to either act as inhibitors (Kotler et al. 1988) or to be hydrolyzed via rate-limiting chemical or physical steps (Polgár et al. 1994; Szeltner and Polgár 1996). This is rather surprising as the chemical characteristics of the peptide bond are expected to be very similar in all cases; therefore, HIV-1 PR-bound peptides might be expected to be cleaved in a similar way. In terms of the flexibility-assisted mechanism presented here, some peptides will form adducts with the protease which might not sample "reactive conformations" because of their particular flexibility properties and thus these ligands will act as inhibitors. Other peptide/protease adducts will easily achieve the proper conformation for cleavage and the rate-limiting step in these cases will be imposed by the chemical catalysis reaction itself. Finally, a third class of peptides will sample "reactive conformations" less often and eventually, achieving the proper conformation, will become rate limiting (i.e., a "physical" step).
|
Conclusions |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
Our calculations suggest that the small chemical changes in going from L63P to M46I-L63P, while not modifying the global structure of the complexes, can induce subtle differences in the dynamics of the protein (especially the flaps) and of the substrate itself. Most interestingly for the present discussion, the M46I mutation strongly affects the overall flexibility of the flaps that induce corresponding changes in the dynamic properties of SUB/INT.
The changes in conformational flexibility in the substrate complexes may play an important role for the enzymatic activity. Indeed, as this motion is crucial for modulating the activation free energy of the reaction (Piana et al. 2002), we propose that the difference in substrate mobility on passing from wild type to M46I is a crucial ingredient for the observed increase of kcat upon mutation (Schock et al. 1996). This `flexibility-assisted catalysis' mechanism might also be effective in other compensatory mutations not involving charged residues (Fig. 1) and may provide a rationale for the different fate of adducts between the protease and a variety of peptides with similar affinity.
|
Materials and methods |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
Protein residues belonging to subunit 1 were numbered from 1 to 99 and those belonging to subunit 2 from 1' to 99'. Substrate residues binding to subunit 1 (2) were numbered from P1 (P1') to P3 (P3') (Berger and Schechter 1970): Thr (P3)-Ile (P2)-Met (P1)-Met (P1')-Gln (P2')-Arg (P3'). Thus, the peptide bond to be cleaved by the enzyme belongs to residues P1 and P1' (Met-Met).
The HIV-1 PR/SUB complex was immersed in a 66.8 x 55.2 x 43.0 Å3 box containing 4170 water molecules. The positive charge of the HIV-1 PR peptide complex (+5) was neutralized by adding five chloride ions close to five positively charged groups not involved in salt bridges in the crystal structure of the enzyme. The total system was composed of 15,749 atoms.
The classical MD simulations were carried out using the AMBER suite of programs (Case et al. 1997). The force-field parameters of the protein, SUB and Cl- were those of the AMBER force field (Cornell et al. 1995) whereas for water the TIP3P model was used.
Electrostatic interactions were calculated with the Ewald particle mesh method, using a 64 x 54 x 45 grid (Darden and York 1993; Essman et al. 1995; Weerasinghe et al. 1995; Duan and Killman 1999) and a cubic interpolation between the points. The motion of the center of mass was removed every 30 ps. Constant temperature and pressure conditions were achieved by coupling the system to a Berendsen's thermostat and barostat (Berendsen et al. 1984) with a relaxation time of 2.0 ps. Bonds involving hydrogen atoms were constrained to their equilibrium position with the SHAKE algorithm. The time step was 1.5 fs.
The system was heated to 150 K in 15 ps, then to 300 K in 15 ps. Subsequently, 1200 ps of equilibration at 300 K were carried out. Following Liu et al. 1996, we imposed position restraints in the cleavage site during the first 700 ps of the equilibration phase. Specifically we restrained the position of the Asp dyad with a harmonic restraint of 1.0 kcal Mol-1 Å2 and the HN(Gly27,27') -O(MetP1,P2') H-bonds (see Chart 2) with one of 0.5 kcal Mol-1 Å2 centered at 2.3 Å. These H-bonds are conserved in the complexes of HIV-1 PR with peptido-mimetic inhibitors for which the X-ray structure has been determined. On the other hand, previous MD studies reported difficulties in maintaining them (Liu et al. 1996). After 700 ps, these constraints were released and 500 ps of further equilibration were carried out.
|
Generalized order parameters (S2) were calculated according to the model-free formulation of Lipari and Szabo (Lipari and Szabo 1982a, b). The order parameters were calculated as MD averages calculated on windows of 100 ps taken along the entire trajectory.
The dynamical cross-correlation matrix Cij of the C
atoms i and j was calculated as (Harte et al. 1990):
 |
denotes an MD-averaged quantity and the instantaneous displacement from the average MD position of atom i during a given time step. Cij varies from -1.0 for completely anticorrelated motions to 1.0 for completely correlated motions. Convergence of the residue rmsd and NMR order parameters were assessed by calculating these properties on different segments of the L63P-M46I/SUB simulation. The results of these control calculations are presented in the supplementary information and indicate that the residue rmsds converge on the 1 ns time scale, while a longer sampling (>5 ns) is required to achieve convergence of the NMR order parameters.
The SUB/INT-active site distance (da) was defined as the average distance (measured on the four Cs) between the Asp dyad and the methionine residues of SUB/INT (Piana et al. 2002) (see Chart 3):
 |
|
|
Electronic supplemental material |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
|
Acknowledgments |
|---|
|
References |
|---|
|
TOPAbstractIntroductionResults and DiscussionConclusionsMaterials and methodsElectronic supplemental materialReferences |
|---|
Berendsen, H.J.C., Postma, J.P.M., Van Gusteren, W.F., DiNola, A., and Haak, J.R. 1984. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81: 3684–3690.[CrossRef]
Berger, A. and Schechter, I. 1970. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 257: 249–264.[Medline]
Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G.L., Bhat, T.N., Weissig, H., Shindyalov, I.N., and Bourne, P.E. 2000. The protein data bank. Nucleic Acids Res. 28: 235–242.
Case, D.A., Pearlman, D.A., Caldwell, J.W., Cheatham III, T.E., Ross, W.S., Simmerling, C.L., Darden, T.A., Merz, K.M., Stanton, R.V., Cheng, A.L., Vincent, J.J., Crowley, M.F., Ferguson, D.M., Radmer, R.J., Singh, U.C., Weiner, P.K., and Kollman, P.A. 1997. AMBER 5.0.
Chen, Z., Li, Y., Schock, H.B., Hall, D., Chen, E., and Kuo, L.C. 1995. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270: 21433–21436.
Collins, J.R., Burt, S.K., and Erickson, J.W. 1995. Flap opening in HIV-1 protease simulated by `activated' molecular dynamics. Nature Struct. Biol. 2: 334–338.[CrossRef][Medline]
Condra, J.H., Holder, D.J., Schleif, W.A., Blahy, O.M., Danovich, R.M., Gabryelski, L.J., Graham, D.J., Laird, D., Quintero, J.C., Rhodes, A., Robbins, H.L., Roth, E., Shivaprakash, M., Yang, T., Chodakewitz, J.A., Deutsch, P.J., Leavitt, R.Y., Massari, F.E., Mellors, J.W., Squires, K.E., Steigbigel, R.T., Teppler, H., and Emini, E.A. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70: 8270–8276.[Abstract]
Cornell, W.D., Cieplack, P., Bayly, C.I., Gould, I.R., Merz, K.M., Ferguson, D.M., Spellmeyer, D.C., Fox, T., Caldwell, J.W., and Kollman, P.A. 1995. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117: 5179–5197.[CrossRef]
Darden, T.A. and York, D. 1993. Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J. Chem. Phys. 98: 10089–10094.[CrossRef]
Duan, Y. and Kollman, P.A. 1999. Pathways to a protein folding intermediate observed in a 1-microsecond simulation in aqueous solution. Science 282: 740–744.
Erickson, J.W. and Burt, S.K. 1996. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36: 545–571.[CrossRef][Medline]
Essman, U., Perera, L., Berkowitz, M.L., Darden, T.A., Lee, H., and Pedersen, L.G. 1995. A smooth particle mesh Ewald method. J. Chem. Phys. 103: 8577–8593.[CrossRef]
Freedberg, D.I., Wang, Y.X., Stahl, S.J., Kaufman, J.D., Wingfield, P.T., Kiso, Y., and Torchia, D.A. 1998. Flexibility and function in HIV protease: Dynamics of the HIV-1 protease bound to the asymmetric inhibitor Kynostatin 272 (KNI-272). J. Am. Chem. Soc. 120: 7916–7923.[CrossRef]
Freedberg, D.I., Ishima, R., Jacob, J., Wang, Y.X., Kustanovich, I., Louis, J.M., and Torchia, D.A. 2002. Rapid structural fluctuations of the free HIV protease flaps in solution: Relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci. 11: 221–232.
Gulnik, S., Erickson, J.W., and Xie, D. 2000. HIV protease: Enzyme function and drug resistance. Vitam. Horm. 58: 213–256.[CrossRef][Medline]
Harte, W.E., Swaminathan, S., Mansuri, M.M., Martin, J.C., Rosenberg, I.E., and Beveridge, D.L. 1990. Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. 87: 8864–8868.
Harte, W.E., Swaminathan, S., and Beveridge, D.L. 1992. Molecular dynamics of HIV-1 protease. PROTEINS: Str. Funct. Gen. 13: 175–194.
Ho, D.D., Toyoshima, T., Mo, H., Kempf, D.J., Norbeck, D., Chen, C.M., Wideburg, N.E., Burt, S.K., Erickson, J.W., and Singh, M.K. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68: 2016–2020.
Hong, L., Zhang, X.C., Hartsuck, J.A., and Tang, J. 2000. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance. Protein Sci. 9: 1898–1904.[Abstract]
Hyland, L.J., Tomaszek, T.A., Roberts, G.D., Carr, S.A., Maagard, V.W., Bryan, H.L., Fakhoury, S.A., Moore, M.L., Minnich, M.D., Culp, J.S., DesJarlais, R.L., and Meek, T.D. 1991. Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange. Biochemistry 30: 8441–8453.[CrossRef][Medline]
Ishima, R., Freedberg, D.I., Wang, Y.X., Louis, J.M., and Torchia, D.A. 1999. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure Fold Des. 7: 1047–1055.[Medline]
Kotler, M., Katz, R.A., Danho, W., Leis, J., and Skalka, A.M. 1988. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc. Natl. Acad. Sci. 85: 4185–4189.
Lau, E.Y. and Bruice, T.C. 2000. Comparison of the dynamics for ground-state and transition-state structures in the active site of catechol O-Methyl transferase. J. Am. Chem. Soc. 122: 7165–7171.[CrossRef]
Lipari, G. and Szabo, A. 1982a. Model free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results. J. Am. Chem. Soc. 104: 4559–4570.[CrossRef]
Lipari, G. and Szabo, A. 1982b. Model free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J. Am. Chem. Soc. 104: 4546–4559.[CrossRef]
Liu, H., Müller-Plathe, F., and Van Gusteren, W.F. 1996. A combined quantum/classical molecular dynamics study of the catalytic mechanism of HIV protease. J. Mol. Biol. 261: 454–469.[CrossRef][Medline]
Luo, X., Kato, R., and Collins, J.R. 1998. Dynamic flexibility of protein-inhibitor complexes: A study of the HIV-1 protease/KNI-272 complex. J. Am. Chem. Soc. 120: 12410–12418.[CrossRef]
Mahalingam, B., Louis, J.M., Hung, J., Harrison, R.W., and Weber, I.T. 2001. Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43: 455–464.[CrossRef][Medline]
Mahalingam, B., Louis, J.M., Reed, C.C., Adomat, J.M., Krouse, J., Wang, Y.F., Harrison, R.W., and Weber, I.T. 1999. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263: 238–245.[Medline]
Mammano, F., Trouplin, V., Zennou, V., and Clavel, F. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug. J. Virol. 74: 8524–8531.
Markowitz, M., Mo, H., Kempf, D.J., Norbeck, D.W., Bhat, T.N., Erickson, J.W., and Ho, D.D. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69: 701–706.[Abstract]
Martinez-Picado, J., Savara, A.V., Shi, L., Sutton, L., and D'Aquila, R.T. 2000. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 275: 318–322.[CrossRef][Medline]
Miller, M., Schneider, J., Sathyanarayana, B.K., Toth, M.V., Marshall, G.R., Clawson, L., Selk, L.M., Kent, S.B.H., and Wlodawer, A. 1989. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 246: 1149–1152.
Nicholson, L.K., Yamazaki, T., Torchia, D.A., Grzesiek, S., Bax, A., Stahl, S.J., Kaufman, J.D., Wingfield, P.T., Lam, P.Y., and Jadhav, P.K. 1995. Flexibility and function in HIV-1 protease [see comments]. Nat. Struct. Biol. 2: 274–280.[CrossRef][Medline]
Pazhanisamy, S., Stuver, C.M., Cullinan, A.B., Margolin, N., Rao, B.G., and Livingston, D.J. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271: 17979–17985.
Piana, S., Parrinello, M., and Carloni, P. 2002. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J. Mol. Biol. 319: 567–583.[CrossRef][Medline]
Polgár, L., Szeltner, Z., and Boros, I. 1994. Substrate-dependent mechanism in the catalysis of human immunodeficiency virus protease. Biochemistry 33: 9351–9357.[CrossRef][Medline]
Poorman, R.A., Tomasselli, A.G., Heinrikson, R.L., and Kezdy, F.L. 1991. A cumulative specificity model for proteases form human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J. Biol. Chem. 266: 14554–14561.
Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C.A. 2000. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301: 1207–1220.[CrossRef][Medline]
Radkiewicz, J.L. and Brooks, C.L. 2000. Protein dynamics in enzymatic catalysis: Exploration of dihydrofolate reductase. J. Am. Chem. Soc. 122: 225–231.
Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.F., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeister, K., Ivanoff, L., Petteway Jr, S.R., Pearson, M.L., Lautenberger, J.A., Papas, T.S., Ghrayeb, J., Chang, N.T., Gallo, R.C., and Wong-Staal, F. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284.[CrossRef][Medline]
Ridky, T.W., Kikonyogo, A., Leis, J., Gulnik, S., Copeland, T., Erickson, J.W., Wlodawer, A., Kurinov, I., Harrison, R.W., and Weber, I.T. 1998. Drug-resistant HIV-1 protease identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37: 13835–13845.[CrossRef][Medline]
Rose, R., Craik, C.S., Douglas, N.L., and Stroud, R.M. 1996. Three-dimensional structures of HIV-1 and SIV protease product complexes. Biochemistry 35: 12933–12944.[CrossRef][Medline]
Rosin, C.D., Belew, R.K., Walker, W.L., Morris, G.M., Olson, A.J., and Goodsell, D.S. 1999. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors. J. Mol. Biol. 287: 77–92.[CrossRef][Medline]
Schaffer, L. and Verkhivker, G.M. 1998. Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 33: 295–310.[CrossRef][Medline]
Schock, H.B., Garsky, V.M., and Kuo, L.C. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271: 31957–31963.
Scott, W.R. and Schiffer, C.A. 2000. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure Fold. Des. 8: 1259–1265.[Medline]
Stebbins, J., Towler, E.M., Tennant, M.G., Deckman, I.C., and Debouck, C. 1997. The 80's loop (residues 78 to 85) is important for the differential activity of retroviral proteases. J. Mol. Biol. 267: 467–475.[CrossRef][Medline]
Szeltner, Z. and Polgár, L. 1996. Rate-determining steps in HIV-1 protease catalysis. J. Biol. Chem. 271: 32180–32184.
Tawa, G.J., Topol, I.A., Burt, S.K., and Erickson, J.W. 1998. Calculation of the relative binding free energies of peptidic inhibitors to HIV-1 protease and its I84V mutant. J. Am. Chem. Soc. 120: 8856–8863.[CrossRef]
Tjandra, N., Wingfield, P., Stahl, S.J., and Bax, A. 1996. Anisotropic rotational diffusion of perdeuterated HIV protease from 15N NMR relaxation measurements at two magnetic fields. J. Bio. NMR 8: 273–284.
Wang, W. and Kollman, P.A. 2001. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. 98: 14937–14942.
Warshel, A. 1978. Energetics of enzyme catalysis. Proc. Natl. Acad. Sci. 75: 5250–5254.
Weerasinghe, S., Smith, P.E., Mohan, V., Cheng, Y.-K., and Pettitt, B.M. 1995. Nanosecond dynamics and structure of a model DNA triple helix in saltwater solution. J. Am. Chem. Soc. 117: 2147–2158.[CrossRef]
Wlodawer, A. and Erickson, J.W. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62: 543–585.[CrossRef][Medline]
Wlodawer, A. and Vondrasek, J. 1998. Inhibitors of HIV-1 protease: A major success of structure-based drug design. Annu. Rev. Biophys. Biomol. Struct. 27: 249–284.[CrossRef][Medline]
Young, B. and Kuritzkes, D.S., 2001. Resistance to HIV-1 inhibitors. In Protease inhibitors in AIDS therapy (eds. R.C. Ogden and C. Flexner). Marcel Dekker, New York.
Zoete, V., Michielin, O., and Karplus, M. 2002. Relation between sequence and structure of HIV-1 protease inhibitor complexes: A model system for the analysis of protein flexibility. J. Mol. Biol. 315: 21–52.[CrossRef][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Trylska, V. Tozzini, C.-e. A. Chang, and J. A. McCammon HIV-1 Protease Substrate Binding and Product Release Pathways Explored with Coarse-Grained Molecular Dynamics Biophys. J., June 15, 2007; 92(12): 4179 - 4187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Siehl, L. A. Castle, R. Gorton, and R. J. Keenan The Molecular Basis of Glyphosate Resistance by an Optimized Microbial Acetyltransferase J. Biol. Chem., April 13, 2007; 282(15): 11446 - 11455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hornak, A. Okur, R. C. Rizzo, and C. Simmerling HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations PNAS, January 24, 2006; 103(4): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Tomatis, R. M. Rasia, L. Segovia, and A. J. Vila From the Cover: Mimicking natural evolution in metallo-{beta}-lactamases through second-shell ligand mutations PNAS, September 27, 2005; 102(39): 13761 - 13766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wittayanarakul, O. Aruksakunwong, S. Saen-oon, W. Chantratita, V. Parasuk, P. Sompornpisut, and S. Hannongbua Insights into Saquinavir Resistance in the G48V HIV-1 Protease: Quantum Calculations and Molecular Dynamic Simulations Biophys. J., February 1, 2005; 88(2): 867 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Perryman, J.-H. Lin, and J. A. McCammon HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs Protein Sci., April 1, 2004; 13(4): 1108 - 1123. [Abstract] [Full Text] [PDF]
|
|
| ||||||
', `x', `*', `
', respectively. Only one of the two monomers is shown for clarity, the other monomer shares very similar patterns.
